SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to news regarding an amended agreement to increase its ownership stake in the Tanbreez rare earth project in Greenland. The community is discussing the implications of this deal, particularly its potential impact on the company's valuation and future prospects, with some suggesting a possible US government stake. Investors are also weighing the connection to other rare earth and lithium plays, and assessing the potential for a significant squeeze.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

ANRO is trending due to recent FDA Fast Track designation for its ALTO-101 schizophrenia treatment, sparking optimism about its potential as a novel solution in a market with unmet needs. The community is discussing the significance of this milestone, potential for accelerated approval, and the company's broader pipeline. Increased trading volume and institutional ownership suggest growing confidence in Alto Neuroscience's prospects.

Hillenbrand, Inc. is a global industrial company, which engages in providing engineered processing equipment and solutions. It operates through the Advanced Process Solutions and Molding Technology Solutions segments. The Advanced Process Solutions segment provides compounding, extrusion, and material handling, screening, and separating equipment, systems, and services for manufacturing and other industrial processes. The Molding Technology Solutions segment includes engineered and customized equipment, systems, and services in plastic technology and processing. It also operates through the following geographical segments: United States, China, India, Germany, and All Other Countries. The company was founded on November 1, 2007 and is headquartered in Batesville, IN.

Hillenbrand Inc

Hillenbrand is trending due to recent strategic moves, including considering a potential sale of the company's plastics division and exploring strategic alternatives for its Batesville business. Unusual options activity suggests bullish sentiment, while the community discusses the company's consolidation and potential for a significant move. Wall Street's EPS expectations and recent insider activity are also being closely monitored.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending following news of trial updates and increased volume, leading to a surge past its 52-week high. Community members are actively speculating about a potential buyout and the implications of new partnerships. Discussions also revolve around the company's financial health and future growth prospects in the competitive pharmaceutical landscape.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction, with community members drawing comparisons to Bitcoin and highlighting its cultural significance. Active discussion also points to links for the coin's website and DEX screener. Some users are expressing concerns about liquidity and exchange availability.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as the community celebrates its recent listing on Robinhood, anticipating increased exposure and potential price growth. Discussions revolve around Floki's long-term potential, comparisons to other meme coins, and predictions for a significant rally. Some community members highlight Floki's ecosystem and utility, differentiating it from other meme coins.

Maplebear, Inc. engages in the design and development of an online application that offers grocery delivery and pick-up services. The firm offers Instacart which enables users to connect with personal shoppers in the area who pick up and deliver groceries from local stores. The company was founded by Apoorva Mehta, Brandon Leonardo, and Max Mullen in 2012 and is headquartered in San Francisco, CA.

Maplebear Inc.

Instacart

Instacart ($CART) is trending as analysts are split amid rising competition from companies like Amazon, DoorDash, and Uber, with some downgrading the stock while others maintain positive outlooks. Community discussions revolve around Instacart's pricing compared to competitors and potential benefits like rewards and exclusive partnerships.  Analyst ratings vary, with price targets reflecting uncertainty about Instacart's ability to maintain market share.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending as investors debate the impact of the European ORLADEYO business sale and await potential acquisitions, with some expressing frustration over the stock's performance despite positive fundamentals and revenue growth. Community sentiment is mixed, with discussions around potential buyouts, short squeezes, and the company's future strategy amid competition in the HAE market. Some traders express concern about further downside, while others remain hopeful for a turnaround driven by upcoming catalysts.

Archrock, Inc. engages in the provision of operations, maintenance, service and equipment for oil and natural gas production, processing, and transportation applications. It operates through the Contract Operations and Aftermarket Services segments. The Contract Operations segment provides natural gas compression services to meet specific customer requirements. The Aftermarket Services segment refers to the provision of services to support the compression needs of customers, from parts sales and normal maintenance services to full operation of a customer’s owned assets. The company was founded in 1954 and is headquartered in Houston, TX.

Archrock Inc

Archrock ($AROC) is trending due to recent positive analyst ratings from Wells Fargo and Mizuho, highlighting the company's leverage amid rising natural gas supply and potential for growth. The community is also discussing Archrock's role in powering AI data centers, with some seeing it as a hidden beneficiary of the AI boom. Recent director share purchases and strong fundamentals, including high fleet utilization, are also fueling interest in the stock.

Weyerhaeuser Co. engages in the manufacture, distribution, and sale of forest products. It operates through the following segments: Timberlands, Real Estate, Energy, and Natural Resources (Real Estate and ENR), and Wood Products. The Timberlands segment manages private commercial forestland worldwide and engages in growing and harvesting trees for lumber, building, pulp, paper, and other wood products. The Real Estate and ENR segment delivers premiums to timber value by identifying and monetizing higher and better use lands and capturing the full value of surface and subsurface assets. The Wood Products segment delivers lumber, structural panels, engineered wood products and complementary building products for residential, multi-family, industrial, and light commercial applications. The company was founded by Frederick T. Weyerhaeuser on January 18, 1900 and is headquartered in Seattle, WA.

Weyerhaeuser Co.

Weyerhaeuser is trending amid discussions around lumber tariffs, housing market conditions, and potential interest rate cuts, impacting its sector. Community members are weighing the effects of these factors on Weyerhaeuser's growth potential, dividend stability, and overall portfolio diversification. Recent analyst ratings and price target adjustments are also fueling the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio logged its fourth straight day of gains on Tuesday, climbing to its highest level in nearly a month as shares broke above the 200-day moving average amid optimism from Anktiva trial data showing survival benefits in lung cancer patients.Technical SetupImmunityBio Investor and former UBS analyst David Din&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DavidDin/status/1967895088643895767">said in a post on X</a> that the stock has finally broken out of a long slump dating back to April 2024, now showing a pattern of “higher highs and higher lows.”&nbsp;<img src="https://news.stocktwits-cdn.com/longterm_downward_trend_jpg_bc73477cdd.webp" alt="longterm downward trend.jpg">He pointed to several bullish indicators: a&nbsp;moving average convergence divergence (MACD) crossover (a signal that momentum is shifting upward) and a divergence in relative strength index (showing buying strength building even while the stock had been falling).<img src="https://news.stocktwits-cdn.com/moving_averages_jpg_47d36e8b5a.webp" alt="moving averages.jpg">He also pointed to a positive signal from the Ichimoku Cloud indicator, which provides both forward- and backward-looking views of market trends. For IBRX, the short-term conversion line (blue) has crossed above the longer-term baseline (red), a move that could signal a bullish shift in momentum.<img src="https://news.stocktwits-cdn.com/ichimoku_cloud_jpg_af4d9c4a78.webp" alt="ichimoku cloud.jpg">Din described the move above the 200-day moving average as “huge,” noting the stock had tested this level before but pulled back, and could now make another attempt to push higher.&nbsp;He marked $3.04 as the next Fibonacci level, comparing the setup to past surges he called “God Candles,” where the stock jumped 20%–27% in a single day and cleared multiple technical barriers.He added that Bollinger Bands, which measure volatility, are starting to widen, similar to October 2024 when a sudden spike helped define the stock’s long-term downtrend. With that trendline now broken, Din said there is no major technical ceiling left to stop another strong move.Din also flagged a gap on the chart at $4.50, predicting it would be filled, and noted that shorter-term moving averages are lining up in a bullish fashion: the 21-day average is nearing a crossover of the 50-day, the 50-day is close to crossing the 125-day, and the 200-day is now within reach.Lung Cancer StudyThe stock’s momentum comes alongside clinical data presented at the IASLC 2025 World Conference on Lung Cancer.&nbsp;ImmunityBio reported that its experimental drug, Anktiva, reversed lymphopenia in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer. Patients showed absolute lymphocyte counts above 1,500 cells/μL, achieving a median overall survival of 21.1 months.On Stocktwits, retail sentiment for ImmunityBio was ‘bullish’ amid ‘high’ message volume, with traders upbeat on strong charts, rising volumes, and fresh buying interest.On Stocktwits, one user noted that ImmunityBio shares were trading around $2.90, describing it as a key resistance level, and said the move higher came with strong momentum, as both price and volume continued to exceed recent averages.<stembedurl>https://stocktwits.com/Bc3345/message/628904525</stembedurl>Another user mentioned they had accumulated several thousand shares in anticipation of a breakout. A third said the three-month chart looked “extremely bullish,” while a fourth remarked that they liked the setup and had taken a large position in the stock.<stembedurl>https://stocktwits.com/Stayinvest/message/628914954</stembedurl><stembedurl>https://stocktwits.com/Thorbig/message/628917335</stembedurl><stembedurl>https://stocktwits.com/OliveGardenCPA/message/628901589</stembedurl><a href="https://stocktwits.com/symbol/IBRX">ImmunityBio’s stock</a> has risen 9.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals

The stock’s recent momentum has been fueled by fresh optimism around trial data for its cancer drug Anktiva, which showed survival benefits in resistant lung cancer patients.

Equity

The last few months have seen a resurgence in social media-driven stock trades,&nbsp;resulting in a crop of new meme stocks,&nbsp;including Opendoor, GoPro, Kohl's, and Krispy Kreme.Now, JPMorgan has identified a few more names to keep a tab on. "We are flagging a few stocks that are heavily mentioned on Social Media and have high Retail buying as well as high Hedge fund Shorting," the investment research said in a note to clients, according to<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/09/11/four-meme-stocks-with-high-social-activity-and-hedge-funds-shorts-according-to-jpmorgan.html">&nbsp;CNBC</a>. "These stocks may experience unexpected flows in case of increased activity."Here are JPMorgan's picks and brief notes on their recent moves:&nbsp;Hims &amp; Hers HealthThe weight loss and health management company's stock has fluctuated significantly between peaks and troughs. Earlier this year, the company entered into a partnership with Novo Nordisk to distribute the latter's Wegovy, a popular GLP-1 weight loss drug. However, a few months later, the Danish pharmaceutical major canceled the partnership, citing Hims &amp; Hers' failure to prevent "knockoff" compounded versions of Wegovy and for engaging in deceptive marketing.U.S. regulators have rapped Hims &amp; Hers for its drug marketing practices, and investors are closely watching the company's moves.Year-to-date gain: 110%Short interest: 31.1%Stocktwits sentiment:&nbsp;Bullish&nbsp;ImmunityBioThe cancer-focused biotech firm has seen interest, driven by clinical-stage Anktiva,&nbsp;designed to boost the immune system's tumor-fighting response, and&nbsp;immunotherapies that target and kill cancer cells. Although the company's stock has mostly&nbsp;traded rangebound this year, shares have jumped double-digit percentages on several occasions in reaction to positive trial data.Year-to-date gain: 0.4%Short interest: 8%Stocktwits sentiment:&nbsp;Bullish&nbsp;Rocket CompaniesThe mortgage and house-owning services firm has seen its stock climb steadily this year, with a recent bump accompanying renewed expectations of a potential lowering of interest rates. The stock hit a 52-week high earlier this week.In March, the Rocket Companies announced a massive $9.4-billion all-stock acquisition of competitor Mr. Cooper Group, lifting investor confidence. The company's business is closely tied to the housing market, which is experiencing a modest rebound.Year-to-date gain: 97%Short interest: 5.3%Stocktwits sentiment:&nbsp;Bullish&nbsp;SoundHound AIAfter a whopping 836% rise in 2024, SoundHound shares have traded comparatively sombrely this year. That said, several analysts have recently begun covering the company, impressed by its voice-based AI technology.In July, the company reported a 217% rise in its second-quarter revenue and increased its sales guidance for the whole year.Year-to-date loss: 29%Short interest: 28.7%Stocktwits sentiment:&nbsp;Bullish&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/rent-the-runway-stocks-plummets-27-after-hours-on-mounting-losses-surging-costs-retail-traders-still-bullish/chw8hPeRdwL">&nbsp;Rent The Runway Stocks Plummets 27% After-Hours On Mounting Losses, Surging Costs — Retail Traders Still Bullish</a>

Traders work on the floor of the New York Stock Exchange during morning trading on August 26, 2025, in New York City. 

Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts

Meme mania has resurged in the past few months.

ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates

ImmunityBio (IBRX) delivered earnings and revenue surprises of 0.00% and +0.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

ImmunityBio's short interest hit a two-month high of 54% this week, representing an increase from under 30% since early March, despite solid&nbsp;first-quarter operational and financial outcomes.&nbsp;The days-to-cover metric decreased from 14.9 to 14.2 as trading volume increased throughout the last two weeks, according to Ortex data, compiled by The Fly.Shares of the pharma firm closed at $2.84, up 6.37% on Friday, before slipping 1.06% to $2.81 in after-hours trading.The company's Q1 2025 net loss was $129.6 million, a minor improvement from the $134.1 million loss&nbsp;a year earlier.ImmunityBio generated net product revenue of about $16.5 million in Q1 ending March 31, 2025, representing a 129% increase from $7.2 million in Q4 2024.&nbsp;The permanent J-code approval for Anktiva helped providers streamline billing and reimbursement, which led to growth.&nbsp;Anktiva is ImmunityBio’s immunotherapy for non-muscle invasive bladder cancer (NMIBC) that helps address the shortage of BCG (Bacillus Calmette-Guérin), a vaccine used to stimulate the immune system against bladder cancer.&nbsp;Unit sales for Anktiva rose by 150% in Q4 2024, while March sales showed a 69% increase over February due to nearly 200 urology practices enrolling in the rBCG Expanded Access Program to overcome the national BCG shortage.CEO Richard Adcock said that Anktiva's revenue growth remained steady because urologists across rural areas began treating NMIBC carcinoma in situ patients with this drug when other treatment options were scarce.&nbsp;ImmunityBio presented positive long-term clinical data from the QUILT 3.032 study concerning Anktiva benefits for non-muscle invasive bladder cancer patients at the American Urological Association meeting in 2025.On Stocktwits, retail sentiment&nbsp;for IBRX was ‘extremely bullish’ amid ‘high’ message volume.One user expressed optimism about ImmunityBio’s stock potentially reaching and closing at $3 the following day, showing a bullish outlook.&nbsp;<stembedurl>https://stocktwits.com/Gee8tch3/message/615048708</stembedurl>Another user predicted that the stock could rise significantly higher in the coming month.<stembedurl>https://stocktwits.com/BullHustler_/message/615041058</stembedurl>The stock has risen 10.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

ImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The Upside

Retail traders showed bullish sentiment following strong Q1 revenue growth and positive clinical data for its bladder cancer drug, despite a 54% jump in short interest.

ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade

Shares of ImmunityBio, Inc. (IBRX) tumbled 18% on Monday afternoon after the company announced that it received a Refuse to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its bladder cancer treatment application.The FDA issues refuse-to-file letters if it identifies deficiencies in a company’s application for drug approval.ImmunityBio <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250505409104/en/ImmunityBio-Requests-an-Urgent-Meeting-With-FDA-to-Address-the-Change-in-the-Agencys-Unambiguous-Guidance-on-Jan-2025-to-Submit-a-sBLA-for-NMIBC-BCG-Unresponsive-Papillary-Disease-Following-an-Inconsistent-Refusal-to-File-Letter-on-May-2-2025">received</a> an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle invasive bladder cancer (NMIBC).ImmunityBio said that the application was submitted in March after all key decision makers at the FDA encouraged it to submit the application “as soon as possible” at an in-person meeting in January.“At this meeting, all key decision makers were specifically asked and unanimously confirmed that ImmunityBio should submit the sBLA as soon as possible based on the data in the single-arm trial,” the company said. &nbsp;The company also said that it has requested an urgent meeting with the FDA to resolve the inconsistencies between the directives it received in January and the letter it recently received, adding that it was “shocked” by the FDA's “inconsistent response.”The company also highlighted that the FDA approved the use of ANKTIVA plus BCG last year for another scenario of NMIBC based on the same trial data that it referred to in the recently submitted application.On Stocktwits, retail sentiment around ImmunityBio jumped from ‘bearish’ to ‘bullish’ over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:629/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_05_at_1_56_52_PM_png_129dd641b3.webp" alt="IBRX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 5, 2025 | Source: Stocktwits" width="629" height="68"><figcaption>IBRX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 5, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> is down by 19% this year and over 73% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apple-escalates-epic-games-fight-with-appeal-stock-falls-after-price-target-cut/chid4BRRb1d">Apple Escalates Epic Games Fight With Appeal – Stock Falls After Price Target Cut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive

ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle invasive bladder cancer (NMIBC).

Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after-hours trading.The rally followed the company’s announcement that the U.S. Food and Drug Administration&nbsp;(FDA) has authorized an expanded access program. This program will provide patients in the U.S. with a critical alternative source of BCG, a standard-of-care treatment for bladder cancer.ImmunityBio said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.&nbsp;A recent Sermo survey of 100 U.S. urologists found that 57% could not treat patients over the past year due to a lack of access to TICE BCG.&nbsp;The Serum Institute of India, the world’s largest vaccine manufacturer by volume, developed the alternative BCG source.In European clinical trials for bladder cancer, ImmunityBio said its recombinant BCG vaccine demonstrated strong immunogenicity with CD8+ and CD4+ T cell stimulation and improved safety compared to earlier BCG strains.<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IBRX_sentiment_and_message_volume_Feb_19_0a49f7ee60.png" alt="IBRX sentiment and message volume Feb 19.png" width="1316" height="316"><figcaption>IBRX sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for ImmunityBio turned even more bullish, with message volume surging by 450% by the end of Wednesday.&nbsp;Retail traders expressed enthusiasm, with one user calling the news “as good as it can get other than a bid” and another speculating that ImmunityBio’s combination therapy with Anktiva could become the new standard of care, replacing Merck’s BCG.<stembedurl>https://stocktwits.com/KNZtime/message/604937174</stembedurl><stembedurl>https://stocktwits.com/Fishbanger51/message/604931186</stembedurl>Shares of ImmunityBio have gained more than 50% so far this year, though short interest, according to Koyfin, climbed from 6.4% at the start of 2025 to 7.7% by the end of last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Light micrograph of a section through a transitional cell carcinoma (TCC, cancer) of the bladder wall. | Image source: Getty Images

ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies

The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE BCG Shortage

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital...

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunity therapy company, today announced the Medicines and Healthcare products Regulatory Agency (MHRA) has validated and accepted the marketing...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$2.54
Prev Close	$2.50
Open	$2.54
Dividend Yield	0.00%
50-Day Moving Average	$2.51
Beta	2.11
Avg. Volume	10.4M
PE Ratio	-5.07

52-Week High	$7.48
52-Week Low	$1.83
Market Capitalization	$2.36B
EPS (Annual)	-$0.6189
Price to Book	-4.01
Revenue Per Employee	$21,683.82
Enterprise Value/EBITDA	N/A

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IBRX News

IBRX ImmunityBio Inc